Skip to main content
TipRanks
Go Ultimate75% OFF

Halozyme (HALO) AI Stock Analysis

1,273 Followers
HALO

Halozyme

(NASDAQ:HALO)

Select Model
Rating:69Neutral
Price Target:$113.00â–²(17.75% Upside)
Action:downgraded
Date:11/07/26

The score is driven primarily by strong profitability and excellent cash generation, supported by a very upbeat earnings outlook with raised guidance. These positives are tempered by meaningful balance-sheet leverage/negative equity and weak near-term technical momentum despite oversold signals. Valuation is moderate and does not add a significant boost without a dividend yield.

Positive Factors
Royalty Portfolio GrowthBroad-based royalty growth across multiple commercial products demonstrates that Halozyme is benefiting from expanding adoption of ENHANZE-enabled therapies. Diversification across partners and indications supports recurring revenue durability and reduces reliance on any single product over the next several quarters.
Negative Factors
High Leverage and Negative EquityElevated debt alongside negative shareholder equity reduces financial flexibility and makes the capital structure more sensitive to any weakening in operating performance. Although cash generation is strong, substantial leverage can constrain investment choices and increase refinancing or repayment pressure.

Halozyme Key Performance Indicators (KPIs)

Revenue by SegmentAnalyzes income from different business areas, highlighting which segments drive growth and profitability, and revealing strategic focus areas.

$0.00$100.00M$200.00M$300.00M$400.00M$500.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Royalties have become the steady, fastest-growing engine for Halozyme, while product sales are increasing but remain lumpy and collaborative-agreement revenue spikes create quarter-to-quarter volatility. That shift points to a more asset-light, high-margin revenue mix driven by partner commercialization and milestones—good for cash conversion but raising dependence on a few partners and timing of launches/payments, so monitor partner concentration and milestone cadence for future upside or downside.

Data provided by:The Fly

Halozyme (HALO) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%HALO+39.15%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$10.94B
Dividend Yield
―
Average Volume (3M)
2.24M
Price to Earnings (P/E)
22.8
Beta (1Y)
0.36
Revenue Growth
45.03%
EPS Growth
-14.29%
Country
US
Employees
423
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Halozyme Business Overview & Revenue Model

Company Description

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHAN...

How the Company Makes Money

Halozyme primarily makes money by licensing its ENHANZE® drug delivery technology to pharmaceutical and biotechnology partners and earning payments tied to those partners’ products. Key revenue streams typically include: (1) Royalties on net sales of...

Halozyme Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-21.95%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by record revenue and royalty results, raised 2026 guidance, broad-based commercial product growth, expanding partner agreements, pipeline advancement and progress with Hypercon and Aerocon. The main negative items were higher operating expenses, adverse initial U.S. patent rulings, ongoing litigation and development and collaboration-revenue timing uncertainties, but these were outweighed by the reported operating momentum and growth opportunities.

Positive Updates

Record Third-Quarter Revenue and Profitability
Total revenue increased 39% year-over-year to $493 million, royalty revenue increased 44% to a record $341 million, adjusted EBITDA increased 35% to $336.2 million, and adjusted EBITDA margin was 68%. Net income increased 41% to $247 million, GAAP diluted EPS increased to $2.01 from $1.43, and non-GAAP diluted EPS increased to $2.39 from $1.72.

Negative Updates

Higher Research and Development Expenses
Research and development expenses increased to $27.8 million from $17.3 million in the prior-year period, reflecting continued investment in advancing ENHANZE and next-generation technology platforms.

Company Guidance

Halozyme raised 2026 guidance to total revenue of $1.86 billion to $1.925 billion, representing growth of 33% to 38% over 2025; royalty revenue of $1.235 billion to $1.255 billion, representing growth of 42% to 45%; product sales of $525 million to $540 million; adjusted EBITDA of $1.24 billion to $1.29 billion, with adjusted EBITDA margin unchanged at approximately 67%; and non-GAAP diluted EPS of $8.75 to $9.05. The company expects 13 ENHANZE programs in clinical development by year-end 2026, Hypercon’s first clinical trial start in the first half of 2027, Aerocon new deal signings in 2027 and clinical entry in the second half of 2028, and up to 13 new products to launch between '29 and 2032, with development timelines of 4.5 to 5.5 years; it plans to provide 2027 guidance and an update on its long-range outlook when it reports fourth quarter results in February.

Halozyme Financial Statement Overview

Summary

Operating fundamentals are strong (high ~82% gross margin, ~27% net margin, and very strong TTM operating/free cash flow near $900M with positive FCF growth). The key risk is the balance sheet: debt is elevated (~$3.25B) and shareholder equity has turned slightly negative, which reduces flexibility and raises leverage risk if operating conditions weaken.

Income Statement

84Very Positive

Balance Sheet

34Negative

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.80B1.40B1.02B829.25M660.12M443.31M
Gross Profit1.48B1.17B855.91M636.89M520.81M361.90M
EBITDA805.64M573.05M656.54M451.95M315.51M259.04M
Net Income485.42M316.89M444.09M281.59M202.13M402.71M
Balance Sheet
Total Assets3.47B2.53B2.06B1.73B1.84B1.10B
Cash, Cash Equivalents and Short-Term Investments1.07B142.82M596.07M336.00M362.79M740.92M
Total Debt3.25B2.14B1.51B1.50B1.51B876.67M
Total Liabilities3.53B2.48B1.70B1.65B1.67B907.48M
Stockholders Equity-55.24M48.81M363.82M83.81M169.80M196.95M
Cash Flow
Free Cash Flow885.88M644.59M468.37M373.28M235.30M297.98M
Operating Cash Flow898.27M651.56M479.06M388.57M240.11M299.44M
Investing Cash Flow-786.38M-545.81M-262.72M-96.91M-487.00M-406.29M
Financing Cash Flow499.30M-85.17M-218.86M-407.99M362.37M77.86M

Halozyme Technical Analysis

Technical Analysis SentimentNegative
Last Price95.97

Price Trends

50DMA114.04Negative
100DMA102.69Negative
200DMA85.66Positive

Market Momentum

MACD-5.35Positive
RSI23.39Positive
STOCH2.09Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HALO, the sentiment is Negative. The current price of 95.97 is below the 20-day moving average (MA) of 116.96, below the 50-day MA of 114.04, and above the 200-day MA of 85.66, indicating a neutral trend. The MACD of -5.35 indicates Positive momentum. The RSI at 23.39 is Positive, neither overbought nor oversold. The STOCH value of 2.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HALO.

Halozyme Risk Analysis

Halozyme disclosed 40 risk factors in its most recent earnings report. Halozyme reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Workforce reduction at federal agencies and changes in U.S. trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners' costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of operations.Q4, 2025
2.Workforce reduction at federal agencies and changes in U.S. trade policy, including recently announced tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners' costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of operations.Q3, 2025
3.Workforce reduction at federal agencies and changes in U.S. trade policy, including recently announced tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners' costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of operations.Q2, 2025

Halozyme Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HALO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ASNDASND84Outperform$16.92B17.22109.18%―93.79%―
HALOHALO69Neutral$10.94B22.83544.26%―45.03%-14.29%
LGNDLGND68Neutral$5.88B112.705.22%―1.03%8.35%
XERSXERS66Neutral$3.07B-416.12-39.52%―38.37%63.43%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ARWRARWR46Neutral$6.08B-8.39-170.58%―-45.65%-11471.36%
IONSIONS42Neutral$4.49B-8.07-120.44%―-0.79%-106.48%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%HALOARWRIONSLGNDASNDXERSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HALO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HALOHalozyme Therapeutics95.9725.7236.61%
ARWRArrowhead Pharmaceuticals, Inc.42.994.0210.32%
IONSIonis Pharmaceuticals Inc.26.96-47.04-63.57%
LGNDLigand Pharmaceuticals Inc293.8187.7642.59%
ASNDAscendis Pharma A/S271.1959.0427.83%
XERSXeris Pharmaceuticals16.809.71136.95%

Halozyme Corporate Events

Executive/Board Changes

Halozyme Therapeutics Adds James Daly to Board

Neutral
Sep 30, 2026

On September 28, 2026, Halozyme Therapeutics elected James Daly to its Board of Directors, placing him in the director class whose term expires at the 2029 annual meeting of stockholders. Daly was not initially assigned to any Board committee and wil...

Business Operations and StrategyPrivate Placements and Financing

Halozyme Raises $1.5 Billion via Convertible Notes Offering

Positive
Sep 22, 2026

On September 22, 2026, Halozyme Therapeutics completed a $1.5 billion private offering of 1.50% Convertible Senior Notes due 2033, receiving about $1.47 billion in net proceeds after fees and expenses. The notes, sold to qualified institutional buyer...

Business Operations and StrategyPrivate Placements and Financing

Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering

Positive
Sep 18, 2026

On September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billion in 1.50% convertible senior notes due October 1, 2033, with an option for initial purchasers to buy an additional $200 million, targeting qualified...

Business Operations and StrategyPrivate Placements and Financing

Halozyme announces $1.05B convertible notes offering

Positive
Sep 16, 2026

On September 16, 2026, Halozyme Therapeutics, Inc. announced a proposed private offering of $1.05 billion in convertible senior notes due October 1, 2033, with an additional $150 million option for initial purchasers, aimed at qualified institutional...

Executive/Board Changes

Halozyme Appoints Dannielle Appelhans to Board of Directors

Neutral
Aug 18, 2026

On August 14, 2026, Halozyme Therapeutics elected Dannielle Appelhans to its Board of Directors, placing her in the director class with terms ending at the 2028 annual meeting of stockholders. She joins as a non-employee director with standard board...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026